Asterias' oligodendrocyte progenitor cell therapy improves motor function in SCI patients at 12 months

Asterias Biotherapeutics Inc. (NYSE-A:AST) reported 12-month data from the Phase I/IIa SCiStar trial to treat cervical spinal cord injury (SCI) showing that 21 of 22 patients

Read the full 264 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE